Retatrutide, developed by Soma Corp., is receiving considerable attention as a innovative therapy for metabolic regulation. This unique medication integrates the properties of a GLP-1 receptor activator and a GIP receptor activator , intended to effectively promote metabolic improvements but also improve related metabolic conditions . Initial clini